Long-term inhibitory effect of the orally active and pure antiestrogen EM-800 on the growth of human breast cancer xenografts in nude mice
Open Access
- 28 January 2000
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 85 (3) , 424-429
Abstract
The antiproliferative effect of the new antiestrogen EM-800 has been studied during 40 weeks of treatment on human breast carcinoma ZR-75–1 xenografts in ovariectomized nude mice supplemented with estrone (0.5 μg, s.c. daily). At the daily 50 μg (approximately 2.5 mg/kg) oral dose, EM-800 caused a complete inhibition of the 680% stimulatory effect of estrone on the growth of the ZR-75–1 human breast cancer xenografts. Complete response, defined as the complete disappearance of the tumors, was observed in 41% of tumors following treatment with the 50 μg dose of the antiestrogen, while a value of 26% was found in ovariectomized animals. The proportion of tumors showing progression at the end of 40 weeks of treatment decreased from 94% in the estrone-supplemented animals to 62%, 61% and 19% in the animals receiving the 5 μg, 20 μg and 50 μg daily doses of the antiestrogen, respectively. None of the tumors that showed a complete or a partial response progressed at later time intervals. The 50 μg daily dose of EM-800 nearly completely (93%) or completely (28% below the value in ovariectomized animals) reversed the stimulatory effect of estrone on uterine and vaginal weight, respectively. The disappearance of 41% of tumors in the group of animals that received the 50 μg daily dose of EM-800 indicates that the antiestrogen induces cell death or apoptosis in ZR-75–1 human breast cancer cells and that its action is cytotoxic and not only cytostatic. Int. J. Cancer 83:424–429, 2000. ©2000 Wiley-Liss, Inc.Keywords
This publication has 12 references indexed in Scilit:
- Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 1999
- (S)-(+)-4-[7-(2,2-Dimethyl-1-oxopro- poxy)-4-methyl-2-[4-[2-(1-piperidinyl)- ethoxy]phenyl]-2H-1-benzopyran-3-yl]- phenyl 2,2-Dimethylpropanoate (EM-800): A Highly Potent, Specific, and Orally Active Nonsteroidal AntiestrogenJournal of Medicinal Chemistry, 1997
- Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancerBritish Journal of Cancer, 1996
- Comparison of the Effects of a Pure Steroidal antiestrogen With Those of Tamoxifen in a Model of Human Breast CancerJNCI: Journal of the National Cancer Institute, 1995
- Original article: Response after withdrawal of tamoxifen and progestogens in advanced breast cancerAnnals of Oncology, 1992
- IntracrinologyMolecular and Cellular Endocrinology, 1991
- The effect of anti-oestrogens on cell growth and progesterone receptor concentration in human endometrial cancer cells (Ishikawa)Journal of Molecular Endocrinology, 1991
- Endocrine therapy testing of human breast cancers in the soft agar clonogenic assayBreast Cancer Research and Treatment, 1985
- Hormone-induced tumor flareEuropean Journal of Cancer and Clinical Oncology, 1985
- The pharmacology and clinical uses of tamoxifenPharmacology & Therapeutics, 1984